Jefferies Financial Group Inc. Invests $994,000 in Revolution Medicines, Inc. (NASDAQ:RVMD)

Jefferies Financial Group Inc. purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 22,725 shares of the company's stock, valued at approximately $994,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RVMD. Barclays PLC increased its holdings in Revolution Medicines by 187.1% during the 3rd quarter. Barclays PLC now owns 294,664 shares of the company's stock valued at $13,362,000 after purchasing an additional 192,021 shares in the last quarter. KBC Group NV increased its holdings in Revolution Medicines by 54.6% during the 4th quarter. KBC Group NV now owns 4,979 shares of the company's stock valued at $218,000 after purchasing an additional 1,758 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Revolution Medicines by 92.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 61,980 shares of the company's stock valued at $2,711,000 after purchasing an additional 29,853 shares in the last quarter. Empowered Funds LLC acquired a new stake in Revolution Medicines during the 4th quarter valued at $5,803,000. Finally, WCM Investment Management LLC acquired a new stake in Revolution Medicines during the 4th quarter valued at $6,798,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Revolution Medicines

In other news, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the transaction, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at $4,489,834.24. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Margaret A. Horn sold 3,058 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the transaction, the chief operating officer now directly owns 153,533 shares of the company's stock, valued at $5,993,928.32. This trade represents a 1.95% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,660 shares of company stock worth $650,406. 8.20% of the stock is currently owned by company insiders.

Revolution Medicines Stock Performance

NASDAQ:RVMD traded up $0.90 during mid-day trading on Friday, hitting $39.98. The company had a trading volume of 2,622,713 shares, compared to its average volume of 1,516,168. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $62.40. The firm has a market cap of $7.45 billion, a P/E ratio of -11.14 and a beta of 1.11. The business's fifty day moving average is $37.56 and its two-hundred day moving average is $41.94.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same quarter in the prior year, the company earned ($0.70) earnings per share. Equities analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RVMD shares. Needham & Company LLC reaffirmed a "buy" rating and set a $57.00 price target on shares of Revolution Medicines in a report on Thursday, May 8th. Oppenheimer increased their price objective on Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Stifel Nicolaus decreased their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Wedbush reiterated an "outperform" rating and issued a $67.00 price objective on shares of Revolution Medicines in a research report on Thursday, May 8th. Finally, Guggenheim decreased their price objective on Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, Revolution Medicines presently has an average rating of "Buy" and a consensus price target of $67.08.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.